Tarsus Pharmaceuticals (TARS) Receivables - Other (2019 - 2026)

Tarsus Pharmaceuticals' Receivables - Other history runs 8 years deep, the most recent figure standing at $16.9 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 876.43% year-over-year to $16.9 million; the TTM figure through Mar 2026 stood at $16.9 million (up 876.43% YoY), while the FY2025 annual figure was $2.1 million, up 57.97% from the prior year.
• Receivables - Other was $16.9 million for Q1 2026 at Tarsus Pharmaceuticals, up from $2.1 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $16.9 million in Q1 2026 to a low of $246000.0 in Q2 2023.
• Historically, Receivables - Other has averaged $2.4 million across 5 years, with a median of $1.3 million in 2024.
• Biggest YoY gain for Receivables - Other was 2774.1% in 2022; the steepest drop was 95.75% in 2022.
• A 5-year view of Receivables - Other shows it stood at $3.6 million in 2022, then tumbled by 69.49% to $1.1 million in 2023, then grew by 18.85% to $1.3 million in 2024, then surged by 57.97% to $2.1 million in 2025, then jumped by 721.78% to $16.9 million in 2026.
• The last three Receivables - Other figures came in at $16.9 million (Q1 2026), $2.1 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.